Petra Tesch
Keine laufenden Positionen mehr
Profil
Petra Tesch held the position of Chief Information Officer at Proact IT Group AB from 2015 to 2023.
Prior to that, she was the Manager of Information Technology Operations at Biovitrum AB from 2005 to 2010.
From 2010 to 2015, she served as the Chief Information Officer at Swedish Orphan Biovitrum AB.
Ehemalige bekannte Positionen von Petra Tesch
| Unternehmen | Position | Ende |
|---|---|---|
| PROACT IT GROUP AB | Chief Tech/Sci/R&D Officer | 01.04.2023 |
| SWEDISH ORPHAN BIOVITRUM AB | Chief Tech/Sci/R&D Officer | 01.11.2015 |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | 01.01.2010 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PROACT IT GROUP AB | Electronic Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
